0P5I.LSE Mauna Kea Technologies SA
- Market cap
- EUR 5.86M
- P/E
- -
- P/B
- -
- ROE
- -4,243.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Jun 2019.
Is 0P5I.LSE undervalued?
Graham numberThe Graham number of Mauna Kea Technologies SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Mauna Kea Technologies SA fundamental analysis
No fundamental analysis for Mauna Kea Technologies SA yet.
Mauna Kea Technologies SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Mauna Kea Technologies SA
Mauna Kea Technologies SA manufactures and sells medical devices in Europe, Middle East, Africa, the United States, Canada, and Asia. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables physicians to monitor disease progression over time, assess reactions as they occur, classify areas of uncertainty, and guide surgical procedures,…
Full company profileMauna Kea Technologies SA financial statements
2019 annualized: Fiscal year 2019 is not finished. Income statement and cash flow are annualized from 4 quarters up to Jun 30, 2019, the balance sheet is the latest quarter. Figures change when the annual report is published.
Mauna Kea Technologies SA annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 Anlz |
|---|---|
| Income Statement | |
| Revenue | 9.18M |
| Gross Profit | 6.64M |
| Operating Income | -12.1M |
| Net Income | -14.0M |
| Balance Sheet | |
| Total Assets | 11.3M |
| Total Liabilities | 11.0M |
| Shareholders' Equity | 331K |
| Ratios | |
| ROE | -4,243.5% |
| ROA | -124.4% |
| Net Profit Margin | -153.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Mauna Kea Technologies SA dividends
Mauna Kea Technologies SA has not paid dividends in the last 3 fiscal years.
Who owns Mauna Kea Technologies SA
- Insiders 24.39%
- Institutions 14.50%
- Public & others 61.12%
- Shares outstanding 25.2M
- Free float 172M
Mauna Kea Technologies SA company profile
- Company name
- Mauna Kea Technologies SA
- Ticker
- 0P5I.LSE
- ISIN
- FR0010609263
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 56
- Fiscal year end
- December
- Address
- 9, rue d'Enghien, Paris, France, 75010
- Phone
- 33 1 48 24 03 45
- Website
- maunakeatech.com
About Mauna Kea Technologies SA
Mauna Kea Technologies SA manufactures and sells medical devices in Europe, Middle East, Africa, the United States, Canada, and Asia. It offers a range of medical devices for gastroenterology, pulmonology, and urology applications. Its product portfolio includes Cellvizio, a real-time in vivo cellular imaging platform that enables physicians to monitor disease progression over time, assess reactions as they occur, classify areas of uncertainty, and guide surgical procedures, and help diagnose and treat patients. The company was incorporated in 2000 and is headquartered in Paris, France.
Mauna Kea Technologies SA management
5- Mr. Alexandre Loiseau Ph.D.Co-Founder, CEO & Chairman
- Mr. Come de La Tour du PinChief Financial Officer
- Ms. Nathalie LecoqChief Operating Officer
- Mr. François Lacombe Ph.D.Chief Scientific Officer
- Mr. Daryl DonatelliPresident of U.S. & Head of Global Marketing